Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy
NCT00283842
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Diabetes type 1 or 2
- Painful symptoms of diabetic neuropathy in the lower extremities extremities for at least 6 months
- Major Depression
- Uncontrolled diabetes
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Mesa, Arizona
- Peoria, Arizona
- Phoenix, Arizona
- Encino, California
- Newport Beach, California
- Walnut Creek, California
- Pueblo, Colorado
- New Britain, Connecticut
- Stratford, Connecticut
- Waterbury, Connecticut
- Ft. Myers, Florida
- Palm Beach Gardens, Florida
- Pembroke Pines, Florida
- St. Petersburg, Florida
- West Palm Beach, Florida
- Lawrenceville, Georgia
- Roswell, Georgia
- Coeur D'Alene, Idaho
- Chicago, Illinois
- Evansville, Indiana
- Des Moines, Iowa
- Madisonville, Kentucky
- Springfield, Massachusetts
- Ann Arbor, Michigan
- Kansas City, Missouri
- St. Louis, Missouri
- St. Louis, Missouri
- Billings, Montana
- Omaha, Nebraska
- Albany, New York
- Flushing, New York
- New York, New York
- Rochester, New York
- Staten Island, New York
- Fargo, North Dakota
- Cincinnati, Ohio
- Dayton, Ohio
- Toledo, Ohio
- Collegeville, Pennsylvania
- Feasterville, Pennsylvania
- Harleysville, Pennsylvania
- Warwick, Rhode Island
- Austin, Texas
- Dallas, Texas
- San Antonio, Texas
- Midvale, Utah
- Salt Lake City, Utah
- Virginia Beach, Virginia
- Lakewood, Washington
- Tacoma, Washington
- Milwaukee, Wisconsin
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy | |||
Official Title ICMJE | A Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group, 13-Week, Adaptive-Design Study of 4 Fixed Oral Doses of DVS SR in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy | |||
Brief Summary | The purpose of this study is to evaluate the safety and efficacy of DVS SR in the treatment of neuropathic pain associated with diabetic peripheral neuropathy. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment | |||
Condition ICMJE |
| |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Allen R, Sharma U, Barlas S. Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy. J Pain Res. 2014 Jun 23;7:339-51. doi: 10.2147/JPR.S55682. eCollection 2014. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Terminated | |||
Actual Enrollment ICMJE | 408 | |||
Original Enrollment ICMJE | 450 | |||
Actual Study Completion Date ICMJE | June 2008 | |||
Actual Primary Completion Date | June 2008 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00283842 | |||
Other Study ID Numbers ICMJE | 3151A5-322 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Study Sponsor ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Verification Date | October 2011 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |